Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection

JaeHee Cheon, Nayoung Kim, Dong Ho Lee, Jin Wook Kim, Jin Hyeok Hwang, Young Soo Park, Jung Mogg Kim, Seong O. Suh, Hyun Chae Jung, In Sung Song

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

BACKGROUND/AIMS: Proton-pump inhibitor (PPI)-based triple therapy for Helicobacter pylori eradication is widely used with considerable failure rate. Bismuth-based, second-line therapy is also associated with failures in more than 20% of cases in Korea. Our aim was to evaluate the efficacy and tolerability of third-line therapy containing moxifloxacin as a rescue in Korea. METHODS: The subjects consisted of 201 patients infected with H. pylori, who were treated with PPI-based therapy, 42 patients treated with bismuth-based after failure of initial PPI triple therapy, and 10 patients treated with moxifloxacin-containing triple therapy after failure of successive initial and second-line therapy. Eradication rate, compliance and side effect rates were compared. RESULTS: The eradication rates of initial, second-line, and third-line therapy were as follows: 67.2%/83.3%, 54.8%/76.7%, 80.0%/88.9% by intention-to-treat and per protocol analysis, respectively. The compliance of patients for each treatment was 98.2%, 90.9%, 100%, respectively. The side effect rate was significantly higher in the bismuth triple therapy than in the PPI- or moxifloxacin-containing triple therapy (p<0.05). CONCLUSIONS: Moxifloxacin-containing triple therapy shows high eradication rate with fewer side effects and good compliance. Thus, this regimen could be used as a rescue therapy.

Original languageEnglish
Pages (from-to)111-117
Number of pages7
JournalThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume45
Issue number2
Publication statusPublished - 2005 Jan 1

Fingerprint

Helicobacter Infections
Treatment Failure
Helicobacter pylori
Proton Pump Inhibitors
Bismuth
Therapeutics
Korea
moxifloxacin
Patient Compliance
Compliance

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Cheon, JaeHee ; Kim, Nayoung ; Lee, Dong Ho ; Kim, Jin Wook ; Hwang, Jin Hyeok ; Park, Young Soo ; Kim, Jung Mogg ; Suh, Seong O. ; Jung, Hyun Chae ; Song, In Sung. / Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection. In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi. 2005 ; Vol. 45, No. 2. pp. 111-117.
@article{e9fd1be39ca443a1bf2863c519af4d37,
title = "Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection",
abstract = "BACKGROUND/AIMS: Proton-pump inhibitor (PPI)-based triple therapy for Helicobacter pylori eradication is widely used with considerable failure rate. Bismuth-based, second-line therapy is also associated with failures in more than 20{\%} of cases in Korea. Our aim was to evaluate the efficacy and tolerability of third-line therapy containing moxifloxacin as a rescue in Korea. METHODS: The subjects consisted of 201 patients infected with H. pylori, who were treated with PPI-based therapy, 42 patients treated with bismuth-based after failure of initial PPI triple therapy, and 10 patients treated with moxifloxacin-containing triple therapy after failure of successive initial and second-line therapy. Eradication rate, compliance and side effect rates were compared. RESULTS: The eradication rates of initial, second-line, and third-line therapy were as follows: 67.2{\%}/83.3{\%}, 54.8{\%}/76.7{\%}, 80.0{\%}/88.9{\%} by intention-to-treat and per protocol analysis, respectively. The compliance of patients for each treatment was 98.2{\%}, 90.9{\%}, 100{\%}, respectively. The side effect rate was significantly higher in the bismuth triple therapy than in the PPI- or moxifloxacin-containing triple therapy (p<0.05). CONCLUSIONS: Moxifloxacin-containing triple therapy shows high eradication rate with fewer side effects and good compliance. Thus, this regimen could be used as a rescue therapy.",
author = "JaeHee Cheon and Nayoung Kim and Lee, {Dong Ho} and Kim, {Jin Wook} and Hwang, {Jin Hyeok} and Park, {Young Soo} and Kim, {Jung Mogg} and Suh, {Seong O.} and Jung, {Hyun Chae} and Song, {In Sung}",
year = "2005",
month = "1",
day = "1",
language = "English",
volume = "45",
pages = "111--117",
journal = "The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi",
issn = "1598-9992",
publisher = "Korean Society of Gastroenterology",
number = "2",

}

Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection. / Cheon, JaeHee; Kim, Nayoung; Lee, Dong Ho; Kim, Jin Wook; Hwang, Jin Hyeok; Park, Young Soo; Kim, Jung Mogg; Suh, Seong O.; Jung, Hyun Chae; Song, In Sung.

In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, Vol. 45, No. 2, 01.01.2005, p. 111-117.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection

AU - Cheon, JaeHee

AU - Kim, Nayoung

AU - Lee, Dong Ho

AU - Kim, Jin Wook

AU - Hwang, Jin Hyeok

AU - Park, Young Soo

AU - Kim, Jung Mogg

AU - Suh, Seong O.

AU - Jung, Hyun Chae

AU - Song, In Sung

PY - 2005/1/1

Y1 - 2005/1/1

N2 - BACKGROUND/AIMS: Proton-pump inhibitor (PPI)-based triple therapy for Helicobacter pylori eradication is widely used with considerable failure rate. Bismuth-based, second-line therapy is also associated with failures in more than 20% of cases in Korea. Our aim was to evaluate the efficacy and tolerability of third-line therapy containing moxifloxacin as a rescue in Korea. METHODS: The subjects consisted of 201 patients infected with H. pylori, who were treated with PPI-based therapy, 42 patients treated with bismuth-based after failure of initial PPI triple therapy, and 10 patients treated with moxifloxacin-containing triple therapy after failure of successive initial and second-line therapy. Eradication rate, compliance and side effect rates were compared. RESULTS: The eradication rates of initial, second-line, and third-line therapy were as follows: 67.2%/83.3%, 54.8%/76.7%, 80.0%/88.9% by intention-to-treat and per protocol analysis, respectively. The compliance of patients for each treatment was 98.2%, 90.9%, 100%, respectively. The side effect rate was significantly higher in the bismuth triple therapy than in the PPI- or moxifloxacin-containing triple therapy (p<0.05). CONCLUSIONS: Moxifloxacin-containing triple therapy shows high eradication rate with fewer side effects and good compliance. Thus, this regimen could be used as a rescue therapy.

AB - BACKGROUND/AIMS: Proton-pump inhibitor (PPI)-based triple therapy for Helicobacter pylori eradication is widely used with considerable failure rate. Bismuth-based, second-line therapy is also associated with failures in more than 20% of cases in Korea. Our aim was to evaluate the efficacy and tolerability of third-line therapy containing moxifloxacin as a rescue in Korea. METHODS: The subjects consisted of 201 patients infected with H. pylori, who were treated with PPI-based therapy, 42 patients treated with bismuth-based after failure of initial PPI triple therapy, and 10 patients treated with moxifloxacin-containing triple therapy after failure of successive initial and second-line therapy. Eradication rate, compliance and side effect rates were compared. RESULTS: The eradication rates of initial, second-line, and third-line therapy were as follows: 67.2%/83.3%, 54.8%/76.7%, 80.0%/88.9% by intention-to-treat and per protocol analysis, respectively. The compliance of patients for each treatment was 98.2%, 90.9%, 100%, respectively. The side effect rate was significantly higher in the bismuth triple therapy than in the PPI- or moxifloxacin-containing triple therapy (p<0.05). CONCLUSIONS: Moxifloxacin-containing triple therapy shows high eradication rate with fewer side effects and good compliance. Thus, this regimen could be used as a rescue therapy.

UR - http://www.scopus.com/inward/record.url?scp=27744484603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744484603&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 111

EP - 117

JO - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

JF - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

SN - 1598-9992

IS - 2

ER -